Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura.

Scully, Marie; Antun, Ana; Cataland, Spero R; Coppo, Paul; Dossier, Claire; Biebuyck, Nathalie; Hassenpflug, Wolf-Achim; Kentouche, Karim; Knöbl, Paul; Kremer Hovinga, Johanna A; López-Fernández, M Fernanda; Matsumoto, Masanori; Ortel, Thomas L; Windyga, Jerzy; Bhattacharya, Indranil; Cronin, Michael; Li, Hong; Mellgård, Björn; Patel, Munjal; Patwari, Parth; ... (2024). Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura. The New England journal of medicine, 390(17), pp. 1584-1596. Massachusetts Medical Society 10.1056/NEJMoa2314793

Text NEJMoa2314793.pdf - Published Version Restricted to registered users only until 2 November 2024. Available under License Publisher holds Copyright. Download (800kB)

BACKGROUND

Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived products) administered as routine prophylaxis or on-demand treatment in patients with congenital TTP is not known.

METHODS

In this phase 3, open-label, crossover trial, we randomly assigned patients in a 1:1 ratio to two 6-month periods of prophylaxis with recombinant ADAMTS13 (40 IU per kilogram of body weight, administered intravenously) or standard therapy, followed by the alternate treatment; thereafter, all the patients received recombinant ADAMTS13 for an additional 6 months. The trigger for this interim analysis was trial completion by at least 30 patients. The primary outcome was acute TTP events. Manifestations of TTP, safety, and pharmacokinetics were assessed. Patients who had an acute TTP event could receive on-demand treatment.

RESULTS

A total of 48 patients underwent randomization; 32 completed the trial. No acute TTP event occurred during prophylaxis with recombinant ADAMTS13, whereas 1 patient had an acute TTP event during prophylaxis with standard therapy (mean annualized event rate, 0.05). Thrombocytopenia was the most frequent TTP manifestation (annualized event rate, 0.74 with recombinant ADAMTS13 and 1.73 with standard therapy). Adverse events occurred in 71% of the patients with recombinant ADAMTS13 and in 84% with standard therapy. Adverse events that were considered by investigators to be related to the trial drug occurred in 9% of the patients with recombinant ADAMTS13 and in 48% with standard therapy. Trial-drug interruption or discontinuation due to adverse events occurred in no patients with recombinant ADAMTS13 and in 8 patients with standard therapy. No neutralizing antibodies developed during recombinant ADAMTS13 treatment. The mean maximum ADAMTS13 activity after recombinant ADAMTS13 treatment was 101%, as compared with 19% after standard therapy.

CONCLUSIONS

During prophylaxis with recombinant ADAMTS13 in patients with congenital TTP, ADAMTS13 activity reached approximately 100% of normal levels, adverse events were generally mild or moderate in severity, and TTP events and manifestations were rare. (Funded by Takeda Development Center Americas and Baxalta Innovations; ClinicalTrials.gov number, NCT03393975.).

Interest & Impact

Downloads

0 since deposited on 02 May 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item